Quality Control of 6-Nitrobenzo[d]thiazol-2-amineIn 2020, Pugh, Kyler W.;Zhang, Zheng;Wang, Jian;Xu, Xiuzhi;Munthali, Vitumbiko;Zuo, Ang;Blagg, Brian S. J. published 《From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition》. 《ACS Medicinal Chemistry Letters》published the findings. The article contains the following contents:
Heat shock protein 90 (Hsp90) is a mol. chaperone that is responsible for the folding and maturation of client proteins that are associated with all ten hallmarks of cancer. Hsp90 N-terminal pan inhibitors have experienced unfavorable results in clin. trials due to induction of the heat shock response (HSR), among other concerns. Novobiocin, a well characterized DNA gyrase B inhibitor, was identified as the first Hsp90 C-terminal inhibitor that manifested anticancer effects without induction of the HSR. In this letter, a library of Hsp90 C-terminal inhibitors derived from a benzothiazole-based scaffold, known to inhibit DNA gyrase B, was designed, synthesized, and evaluated. Several compounds were found to manifest low micromolar activity against both MCF-7 and SKBr3 breast cancer cell lines via Hsp90 C-terminal inhibition.6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) were involved in the experimental procedure.
6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Quality Control of 6-Nitrobenzo[d]thiazol-2-amine) inhibits the activity of amines, which are small molecules found in many pharmaceuticals. The chemical structure of this drug contains one or more methylene groups that can be activated by diazonium salt to form an intermediate molecule with a reactive amine group.
Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica